202 related articles for article (PubMed ID: 19568254)
1. Preventing and treating biologic-associated opportunistic infections.
Winthrop KL; Chiller T
Nat Rev Rheumatol; 2009 Jul; 5(7):405-10. PubMed ID: 19568254
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic Infections in Biological Therapy, Risk and Prevention.
Bryant PA; Baddley JW
Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
[TBL] [Abstract][Full Text] [Related]
3. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
4. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
5. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
6. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
7. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
Winthrop KL
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
[No Abstract] [Full Text] [Related]
8. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
9. [Infectious complications associated with the use of tumor necrosis factor antagonist drugs: a review].
García-Lechuz Moya JM
Enferm Infecc Microbiol Clin; 2005 Nov; 23(9):551-9. PubMed ID: 16324568
[TBL] [Abstract][Full Text] [Related]
10. The yin and yang of tumor necrosis factor inhibitors.
Calabrese L
Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis and biologics in rheumatology: A special situation.
Handa R; Upadhyaya S; Kapoor S; Jois R; Pandey BD; Bhatnagar AK; Khanna A; Goyal V; Kumar K
Int J Rheum Dis; 2017 Oct; 20(10):1313-1325. PubMed ID: 28730751
[TBL] [Abstract][Full Text] [Related]
12. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
14. [Tuberculosis associated with anti-TNF therapy].
Takeno M; Murakami S; Ishigatsubo Y
Nihon Rinsho; 2007 Jul; 65(7):1308-13. PubMed ID: 17642248
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis infections and tumor necrosis factor alpha antagonists.
Gan J; Manadan AM; Sequiera W; Block JA
Am J Ther; 2013 Jan; 20(1):73-8. PubMed ID: 21519217
[TBL] [Abstract][Full Text] [Related]
16. [Non tuberculous anti-TNF associated opportunistic infections].
Marie I; Guglielmino E
Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
[TBL] [Abstract][Full Text] [Related]
17. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay.
Chen DY; Shen GH; Chen YM; Chen HH; Hsieh CW; Lan JL
Ann Rheum Dis; 2012 Feb; 71(2):231-7. PubMed ID: 22021896
[TBL] [Abstract][Full Text] [Related]
18. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
[TBL] [Abstract][Full Text] [Related]
19. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis and opportunistic infections: relevance to biologic agents.
Bieber J; Kavanaugh A
Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S126-33. PubMed ID: 15552526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
